European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017

 European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6
                               Billion by 2017

  PR Newswire

  DALLAS, April 3, 2013

DALLAS, April 3, 2013 /PRNewswire/ --

The European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET
Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131,
Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes
(Deuterium, C-13) - Global Trends & Forecast to 2017].

Browse >>

  *133 market data tables
  *29 figures
  *292 pages and an in-depth Table of Content on "European Nuclear Medicine
    / Radiopharmaceuticals Market "

Early buyers will receive 10% customization on this report.

This report studies the European nuclear medicine market over the forecast
period 2012-2017.

The European radiopharmaceutical market was valued at $1.1 billion in 2012 and
is poised to reach $1.6 billion by 2017 at a CAGR of 6.8%.

The radioisotopes market is categorized into diagnostic and therapeutic
applications. The diagnostic market consists of PET and SPECT technologies,
while the therapy market comprises of beta emitters and brachytherapy seeds.
The SPECT market accounted for a major share of the diagnostic segment in
2012. Significant radioisotopes in the SPECT diagnostic market are Tc-99m, Tl-
201, Ga-67, and I-123, while PET market is dominated by F-18 and Rb-82. The
therapy market is led by I-131, Sm-153, Re-186, Y-90, and Lu-177. Alpha
emitters are being developed and considered for cancer treatment, however not
available commercially.

It is estimated that Tc-99m diagnostic procedures are expected to increase by
more than 15% in mature markets of Europe, and other developed regions between
2010 and 2030, however shortage of Mo-99/Tc-99m has been a threat to this
industry. The scheduled shutdown of the NRU reactor in Canada in 2016 and
OSIRIS in France in 2018 is a major risk for manufacturers in the near future.
Companies have increased the production of thallium to meet the shortage, as
it is the most commonly used substitute for technetium-99 in cardiac-stress
tests, conducted to evaluate the functioning of coronary arteries.
Radiopharmaceuticals in neurological applications such as Alzheimer's disease,
Parkinson's disease, and dementia are also being preferred by practitioners
besides conventional treatment. Further, upcoming radioisotopes such as Ra-223
(Alpharadin) and Ga-68 possess huge potential for clinical applications.

Increasing use of SPECT and PET scans, technical advancements in equipment and
other factors such as rising awareness of radiopharmaceuticals among
physicians, alpha radioimmunotherapy based targeted cancer treatment, and
ready availability of radiopharmaceutical from cyclotrons have driven the
market. High cost of devices using radioisotopes, short half-life, lack of
good manufacturing practices, and stringent regulatory approvals are major
hurdles to growth of the market.

Germany is the dominant market for diagnostic radioisotopes with 25% share.
Over 120 PET-CT facilities contributed significantly to the German market in
2012; the region had around 600 gamma cameras and 76 PET (PET/CT) scanners.
Cross sectional imaging like SPECT (SPECT/CT) and PET (PET/CT) are majorly
preferred. Among different European countries, Russia, Turkey, and Czech
Republic will be significant due to rising healthcare budgets and increasing
popularity of different European nuclearmedicinemarket in various clinical
indications. Processors such as Covidien Plc., and other players from
different geographies run reactors that are involved in the irradiation of
U-235 to make crude isotopes. They follow various strategies to achieve
sustainable growth, one of which is shifting to Low Enriched Uranium (LEU)
from High Enriched Uranium (HEU). These key players were mainly involved in
strategic agreements and contracts with other institutes and players, while
generator manufacturers followed several strategies to maintain a sustainable
supply chain.

The stable isotopes market was less than $25 million in 2012 and poised to
grow at more than 8.0% CAGR in the next 5 years. Carbon-13 commanded the
largest share of the European stable isotope market in 2012; however deuterium
and oxygen show tremendous potential to grow in the near future. The market
was dominated by two players, Cambridge Isotope Laboratories (CIL) (U.S.) and
Isotec (Sigma Aldrich) (U.S.) in 2012 jointly contributing more than 50% to
the European stables revenue.

Buy a copy of this report @

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in
the U.S. We publish strategically analyzed market research reports and serve
as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles,
databases, and custom research services. MarketsandMarkets covers thirteen
industry verticals; including advanced materials, automotives and
transportation, banking and financial services, biotechnology, chemicals,
consumer goods, telecommunications and IT, energy and power, food and
beverages, industrial automation, medical devices, pharmaceuticals
,semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository.

Contact: Mr.  Rohan North - Dominion Plaza, 17304 Preston Road, Suite
800,Dallas, TX75252 Tel: +1-888-6006-441 Email:
Visit MarketsandMarkets Blog @ Connect
with us on LinkedIn @
Press spacebar to pause and continue. Press esc to stop.